Rudin, C. M., Mountzios, G. S., Sun, L., Cho, B. C., Demirci, U., Baka, S., Gümüş, M., Lugini, A., Ciuleanu, T., Ahn, M., Rocha, P., Zhu, B., Blackhall, F. H., Yoshida, T., Owonikoko, T. K., Paz-Ares, L. G., Huang, S., Gauto, D. M., Recondo, G., Schuler, M. (2025). Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.17_suppl.lba8008